A B S T R A C T To evaluate the interaction of phenylbutazone with racemic warfarin or R,S-(±)-warfarin in man, S-(-)-warfarin or levowarfarin was synthesized with 13C label in the 2-position of the coumarin nucleus and added to [12C]R(+)-warfarin or dextrowarfarin to fonri a [12C/13C]pseudoracemiiate of warfarin. In six normal human subjects, a single oral dose of this "cold labeled" pseudoraceemate, 1.5 mg/kg body weight, was administered with and without a daily dosage of phenylbutazone, 300 milg orally, beginning 3 d before the warfarin dose and continuing throughout the hypoprothrombinemia. Plasma samples were obtained daily and analyzed for warfarin content and for onestage prothrombin activity. Unchanged warfarin in the plasma was fractionate(d by normal-phase, high-pressure liquid chromatography, and the enantiomorphic ratios were determined by chemical-ionizationi mass spectrometry with pentadeuteriowarfarin as the internal standard. A highly significanit augmnentation of the hypoprothrombinemia of the pseudoracemate occurred during the phenylbutazone regimen (P < 0.001) compared with pseudoracemiiic warfarin adminiistered alone. There was a highly significant increase in the plasmna clearance of dextrowarfarin (P < 0.01) and a significant decrease in the plasma clearanice of levowarfarin (P < 0.05) during the phenylbutazone regimen compared with administration of warfarin alone. It was concluded that phenylbutazonie augmented the hypoprothrombinemnia of pseudoracemic warfarin stereoselectively by inhibiting the metabolic disposition of the imore hypoprothrombinemiiic levowarfarin, yet reduced the plasma levels of pseudoPortions of this work were presented at the 37th Anntual Meeting of the Federation of Amiierican Society of Experimental Biology, Atlantic City, N. J., 10 April 1978 anid have been publishecl in abstract form in 1978. Fed. Proc. 37: 545. 
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INTRODUCTION
The interactioni of phenylbutazone and racemiic warfarin in man is paradoxic in that the augmentation of the anticoagulant effect is associated with a more rapid eliminationi of total warfarin (1) . This effect was said to result from dlisplacemenit of the warfarin in plasmna from its albumin-binding sites by the more highly bound phenylbutazone resulting in an increased fraction of free warfarin. Lewis et al. (2) reported a differential effect of phenylbutazone on the enanitiomnorphs of racemiiic warfarin, S-(-)-warfarin (levowarfarin) anid R-(+)-warfarin (dextrowarfarini) (2) . They found that phenylbutazone de- creased the clearanee from plasmiia of' levowarfariin, the more potent anticoagulant agent, and markedly increase(l the clearance of dextrowarfarin. Another study in manl on1 the interaction of phenylbutazone with the separated enantiomniorphs showed augmiientation of the hypoprothrombinemiiia and an increase in plasma conicenltrationis of levowarfarini, n1o significant alteration of the hypoprothromnbinemia ancd a miiarked decrease in plasmna concentrations of' (lextrowarfarin (3) . To determinle simuliltaneously the fate of' both enantiomorphs of racemiic warf:arini, the formii used clinically, levowarfarin was synithesizedl with a stable isotope of carbon, 13C, in the 2-positioni of the coumarin nucleus (4) . By combining the [13C]levowarfarin with an equal amount of commiiilon ['2C]dextrowarfarin, a ['2C/'3C]warfarin pse u(loracemaite was prepared (5) . This preparationi was a(linllilistere(l to normal huiman subjects to stud(ly the simutiltaneouis interactioln of phenylbutazone with each enantiomilorph of racemic warfajrin. METHODS Subjects. Six male subjects, 18-30 yr old, were studied. All were paid volunteers who were carefully informed of the nature of the experiments and who signed written consents in accordance with all the conditions required by federal regulation and the local Research and Human Subject Review Committee. All were in excellent health and had not taken any other drug during the preceding 2 mo. Each subject served as his own control and the order of the experiments with warfarin alone and with warfarin plus phenylbutazone in the crossover studies was assigned randomly. The data were analyzed by Student's t test for paired observations; P values were determined from probability tables for one-tailed tests (6) .
Measurement of anticoagulant effect. The one-stage prothrombin activity was determined by the method of Quick, as described previously (7) , in which the test result in seconds was converted to percentage of prothrombin activity by a saline-dilution curve of pooled normal plasma. The total hypoprothrombinemic effect for each experiment during the control period in which warfarin was administered alone was determined by measuring the total area under the curve (AUC)I for the one-stage prothrombin time expressed in seconds on a semilogarithmic scale by the trapezoidal rule and was expressed in arbitrary units (7) . The increase in AUC-prothrombin time for each subject was determined for the experimental period in which pseudoracemic warfarin plus phenylbutazone were administered.
Synthesis and preparation of ['2C/'3C]pseudoracemlate of warfarin. (S)-warfarin containing 90% enriched 13C exclusively in the C2 position was synthesized as described separately (4). The pseudoracemic mixture was preparedl by recrystallization from an acetone solution containing 1.0 g each of 13C (S)-warfarin -C2-(90%) and (R)-warfarin. The purity of the crystalline material obtained was established by analysis on high-pressure liquid chromatography (HPLC), five different thin-layer chromatographic systems, and by chemical ionization mass spectrometry. Gelatin capsules with a 200-mg capacity, containing either 1, 2, 5, 10, 25, or 50 mg of pseudoracemic warfarin in a lactose (U. S. Pharmacopeia) matrix were prepared for administration. The biologic authenticity of the pseudoracemate as powder in capsules was verified by comparing its hypoprothrombinemic effect and its blood levels to that of true racemic warfarin as tablets in these same six subjects. For racemic and pseudoracemic warfarin, the mean+SEM for AUC-prothrombin time were 90±+12 and 85±+10 U, respectively, an insignificant difference (t, 0.68, P > 0.4). The blood levels measured as AUC-warfarin were 616+63 and 630+34 mg/liter x h for racemic and pseudoracemic warfarin, also an insignificant difference (t, 0.40, P > 0.4).
Preparation of plasma specimens for measuremenit of warfarin. Details of the analytical methodology have been reported separately (5) . A brief description of the method follows. Serial plasma samples, 2 ml, were spiked with 10 jig of the internal standard, pentaphenyldeuteriowarfarin, acidified with hydrochloric acid and extracted with 1,2-dichloroethane. The organic layer was extracted with 2.5 N sodium hydroxide and discarded. The basic aqueous layer then was acidified with hydrochloric acid and extracted with 1,2-dichloroethane. An and 240 h after the administration of pseudoracemic warfarin. The blood was mixed in glass tubes in a proportion of 9:1 with a combiniation of three parts 0.1 M1 sodiumil citrate and two parts 0.1 M citric acid, and centrifugedl at 2,500 rpm for 30 min at 4°C. The plasma was removed an(d stored in several small glass tubes at -20°C.
After a 4-wk rest period, the same subject received 1 100-mg tablet of phenvibutazone (Butazolidin; Geigy Pharmaceuticals, Arclslev, N. Y.), 3 times/d: before breakfast, before dinner, ancl at bedtime. On the 4th d of the phenylbutazone regimen, each subject received the same dose of pseudoracemic warfarin as before; 1.5 mg/kg body vt. The daily regimen of phenylbutazonie was continued for the duration of the hvpoprothrombinemiiia, 6-12 cl, anid then was discontinued. Venous bloodl samples were obtained at the same times as during the control period of pseudloracemiiic warfarin alone and were processed in the same manner. No side effects from either drug were observed in any subject.
Each subject also received a single dose of truly racemic warfarin sodium (Coumadin sodium; Encdo Laboratories, Inc., Garden City, N. Y.) alone, 1.5 mg/kg orally as tablets. Daily blood samples were obtained to determine the blood concentrations of racemic wxarfarin and the prothrombill-tillme responses for each subject for dlirect comiiparison of these parameters with those obtained with pseudoracemic iwarfarin acid.
Calculatiotns. The half-life of the termninal eliminiationi phase of the log plasma warfarin from 12 to 144 h was cal-ctilated by the method of least squares. The slope of the terminal phase, 8, was calculated from the quotient of the facetor 0.693 and the half-life for each sulbject. The plasma concentration of warfarin at time zero, Cp°, was calculated bv extension of the least s(quares line for half-life to time zero.
The apparent voluime of distribution, Vd, was caleculated from the (quiotient of the dose of warfarin anid plasina conicentration at timiie zero for each stubject. The area under the cturve for the plasma concentrations of each enantiomorph of warfarin, AUC-warfarin, wvas determined froin timne 0 to 240 h bv the trapezoidal ruile. The plasmiia clearance of each enantiomorplh of wvarfarin for each subject wvas calcuilated fromii the miiean of the prodtuct of Vd and 8 and fromii the (imiotient of the warfarin dose anid AUC-warfarin.
RESULTS
I12C]R( +)-warfarini. After a(diniistration of the warfharin pseuidoracemn<ate alone, all subjects had detectabl e concentrations of dextrowarfariin in their plasml-a at 1 h (Fig. 1) . The highest concentration of dextrowarfarin was achievedl at 2 h in one stubject, at 4 h in three subjects, at 8 h in one sul)ject, and at 12 h in one subject.2 The highest meani concentration of dlextrowarfarini in plasina occurre(d at 4 h. When the warfarin pseudoracemiate was administered during the phenylbuitazone regimnen, all of the suibjects had detectable concentrations of dextrowarfarini in plasmna at 1 h and had the highest imean concentration at 8 h.
Thle highest concentration of (lextrowarfarin during the phenyvlbuttazonie regimeni was achieve(d at 2 h in one subject, at 4 h in one suibject, at 8 hi in three subjects, and at 12 h in one subject. The highest mean concentrationi of dextrowarfarin in plasmiia duiring the phenylbutazone regimen occurred at 8 h, compared with 4 h for dextrowarfharin alone. The mean concentration of' dextrowarfarin dturing the phenylbutazone regi men compared witlh dextrowarfarin alone was significantly lower at 1 h (P < 0.05) and 2 h (P < 0.03). Thus, the phenylbuutazone regimein resuilted in a slower rate of absorption of dextrowarfarin fiom the psenidoracemate.
After the peak concentrations were reached, the plasmiia concentrations of dextrowarfarin declined l)y app)arent first-order kinetics in all subjects for the dluration of the experi menits 1)oth with and without phenylbutazone (Fig. 1) was reduiced to a highly significant degree (P < 0.002) ( Table I) .
[I3C]S(-)-warfarin. When the warfarin pseuidoracemiate was adcministered alone, all sutbjects had detectable concentrations of levowarfarini at 1 h (Fig. 1) . The highest concentration of levowarfarin was achieved at 2 h after the adml-iinistration of warfarini in one subject, at 4 h ini three subjects, at 8 h in one subject, and at 12 h in one subject. The highest mean concentration of levowarfarin in plasma occurred at [I2CI13iCR,S( ±)twarfarin. After adminiistration of the warfirin pseeudoracemnate alone, the highest concenitration of racemiiic warfarin in plasma was achieved at 2 h in one subject, at 4 h in fOur subjects, an(d at 8 h in one subject. The higlhest miiean conicenitrationi of racemiiic warfarin alone occuirred at 4 h. When the warfarin psemidoracemiiate was adminiistere(d dcuring the phenll butazone regimen, the higlhiest concentration of racemic warfarin in plasmna was achieved at 2 h in one sulbject, at 4 h in two subjects, at 8 h in two subhjects, and at 12 h ini one subject. The highest meani concentration of racemic warfarin dutring the phenylbuitazone regimen occiurred at 8 h, compared with 4 h for warfarin alone. The meani concentration of racemic wvarfarin (Iliritng the phenylbutazone regi men compared with racemic xwarfarin alonie was significantly lower both at I and 2 h (P < 0.05). Thus, the phenyllbitazone regimnen resuilted in a slower rate of absorption of racemic warfarin from the pseudoracemnate.
After the peak concenitrations wvere reached, the plasmat concentrations of racemnic warfarin declined by apparenit first-ordler kinetics in all suibjects for the dIuration-of' the experimiients 1oth with andl without phenylbuitazone. The imean concentrations of racemic wvarfarin durinig the plhenyll)utazone regimen were significantly different fromn adminiistration of warfarin alonie only at 60 and 84 h (P < 0.02). The total AUCwvarfarin for racemic warfarin duiiring the phenN l-butazone regimen was reduced for all subjects. The mean AUC-warfarin for racemic warfarin during the phenylbtutazone regimen compared with that for racemnic warfarin alone was reduced to a highly significant degree (P < 0.01) ( Table I) .
One-stage prothrombin activity. After administration of the single dose of the warfarin pseudoracemiate alone, all six subjects had detectable hypoprothrombinemia after 12 h (Fig. 1) . The most marked depression occurred 48-96 h after the warfarin dose, and the return to 100% of normal activity occurred 144-240 h after it. The mean of the lowest one-stage prothromibin activity occturred at 60 h. The magnitude of the AUC-prothrombin time for the one-stage prothrombin activity varied fromi 56 to 121 U; the nean±SEM for AUC-prothrombin time was 85± 10 U.
After adiministration of the warfarin pseudoracemiate during the phenylbutazone regimen, all six subjects had detectable hypoprothrombinemia after 12 h. The most mlarked depression occurred 72-120 h after the warfarin dose, and the return to 100% of normal activity occurred at 240 h in three subjects and occurred after 240 h in the other three subjects. The mean of' the lowest one-stage prothroimbin activity occutrred 84 h after the warfarin dose during the phenylbutazone regimeni, coimpared with 60 h after the warfarin dose alone. The difference between the mean of' the hypoprothromnbinemnia for warfarin alone and during the phenylbutazone regimen in the first 36 h after the warfarin dose was not significant, from 48 to 60 h was significant (P < 0.02), from 72 to 216 h was highly significant (P < 0.01), and was not significant at 240 h. The AUC-prothrombin time for the one-stage prothrombin activity increased markedly in all six subjects. The mean±SEM was 158±13 U, compared with a mean AUC-prothrombin time for warfarin alone of85± 10 U, a highly significant augmentation (P < 0.001) of the hypoprothrombineimia during the phenylbutazone regimeni. (Table I ). The means of plasma concentration at time zero and of Vd for warfarin alone were not significantly different from those for warfarin during the phenylbutazone regimen. The mean Vd was 9.0 liters for the warfarin alone and 8.8 liters for warfarin during the phenylbutazone regimen, or 11.9 and 11.7% of the average body weight, respectively. The mean±SEM for the half-life of dextrowarfarin was 41.2±+1.7 h for warfarin alone and 26.4±1.6 h for warfarin during the phenylbutazone regimen, a highly significant difference (P <0.001). (Table I ). The meani Vd was 7.8±0.6 liters for warfarin alone and 9.3±0.4 liters for warfarin during the phenylbutazone regiinen, a highly significant difference (P <0.01), anid were 10.3 and 12.3% of body wt, respectively. The mean SEM for half-life of levowarf:arin was 30.5±+5.7 h for warfarin alonie and 40.0±3.8 h for warfarin during the phenylbutazone regimen, a significant difference (P < 0.05). The mean+SEM for AUC-warfarin was 277±33 mg/ liter x h for warfarin alone and 327±25 mg/liter x h for levowarfarin durinng the phenylbutazone regimen, a significant differenice (P < 0.05). The mean±SEM for plasina clearance was 3.52±0.46 ml/min for warfarin alone and 2.86±0.24 ml/min for warfarin during the phenylbutazone regimnen, a significant decrease in levowarfarin clearance (P < 0.05).
Pharinacokinetic analysis of plasma concentrations of pseudoracemic warfarin. A pharmacokinetic analysis of pseudoraceinic warfarin after single doses of the warfarin pseudoraceinate was undertaken on the sum of the plasma concentrations of [12C]R(+)warfarin and I[3C]S(-)warfarin for each subject at every time tested.
The means for Vd were not significantly different for warfarin alone and for warfarin during the phenylbutazone regimen. The mean Vd was 8.8 liters for pseudoracemic warfarin alone and 9.2 liters for pseudoracemnic warfarin during the phenylbutazone regimen, or 11.7% and 12.2% of body wt, respectively. The mean±SEM half-life was 36.2±3.2 h for pseudoraceinic warfarin alone and 33.9±1.8 h for pseudoracemic warfarin during the phenylbutazone regimen, an insignificant difference. The mean±SEM for AUCwarfarin was 630±34 mg/liter x h for pseudoracemic warfarin alone and 528±41 mg/liter x h for pseudoracemic warfarin during the phenylbutazone regimen, a significant difference (P < 0.01). The mean±SEM for plasma clearance was 2.96±0.26 ml/min for warfarin alone and 3.43±0.27 ml/min for warfarin during the phenylbutazone regimen, a significant increase in pseudoracemic warfarin clearance (P < 0.05).
DISCUSSION
The authenticity of pseudoracemic warfarin in both its synthesis and preparation was validated by direct comparison with commercial racemic warfarin in all the research subjects. The total hypoprothrombinemic effect was evaluated by comparison of the mean AUC-prothrombin time for pseudoracemic warfarin and for racemnic warfarin. The mean difference was insignificant. Similarly, there was no significant difference in the AUC of the blood concentrations achieved when pseudoracemic and racemic warfarin were comipared. The hypoprothrombinemic effect of pseudoracemic warfarin with daily phenylbutiazone administration was 186% of the control value, which is similar to the augmentation by phenylbutazone previously reported for racemic warfarin in normnal subjects (1, 2 Although the interaction of warfarin and phenylbutazone has been previously studied with racemic warfarin (1, 2) and with the separated enantiomnorphs of warfarin (2) , no previous data have been published on the fate of each enanitiomorph in racemic warfarin during the interactioni. This approach is important because of the widely divergent effects of phenylbutazone on the enantiomorphs of warfarin. Lewis and Trager (2) found in two subjects that phenylbutazone speeded up the metabolic disposition of dextrowarfarin and slowed down the metabolic disposition of levowarfarin in plasma. They studied the urinary metabolic products of racemic warfarin with and without phenylbutazone in two other subjects andl coneluded that the effect of phenylbutazone on the warfarin enantiomorphs administered together was similar to that on the separated enantiomorphs (2) Phenvlbutazone seemied to slow the gastrointestinial absorption rate of both dextrowarfarin and( levowarfarin, as well as pseudoracemic warfarin. This effect of phenylbutazone on the absorption rate of warfarini hitherto has not been reported. These findings probably were not observed before because previous investigations of this drug interactioni didl not inclti(le early blood samplinig. Racemic warfarin is completely absorbed in normal subjects, whereas the oral anticoagulant dicumarol is not (8) . The absorptioni of racemic warfarin was not affected even by diseases associated with severe gastrointestinal malabsorption. Cholestyramine in man interfered with the absorption of racemic warfarin causing it to appear in the stool (9) , and also interfered with the absorption and subsequent hypoprothrombinemic effect of racemic phenprocoumon (10) . Barbiturates did not affect the absorption of racemic warfarin, but did reduce the absorption of dicumarol (11) . Antacid therapy had no effect on the absorption of racemic warfarin (12) . The simultaneous ingestion of food interfered with the rate but not the extent of absorption of racemic warfarin in man (13) , and actually enhanced the absorption of poorly absorbable dicumarol in one study in man (14) . Thus, the impact of phenylbutazone on the absorption of pseudoracemic warfarin is similar to that of food: reduction in the rate, but not the extent of racemic warfarin absorption, and no effect on its bioavailability or hypoprothrombinemic effect.
Racemnic Perhaps, the effect of phenyll)utazone on the absorption rate of pseudoracemiiic warfarin acid, dextrowarfarin acid, and levowarfarin acid wouild not have occurred with the formii used clinically, racemnic warfarin soditumii. However, this possibility is unlikely both becautse of' conversion to warfarin acid on contact with the acid content of the stomiach, and becautse previotis sttudies in man comnparinig tablets of racemnic warfarin acid to racemic warfairini sodiumln showed no significant differences in the gastrointestinal absorptioni rate of the drug, bioavailability, timie of peak 1)lood levels, AUC-warfarin, AUC-prothrombin time, Vd, or half-life (8, 15) .
The following imechaniismi cani l)e proposecl for the interactioni of phenylbutazone with racemic Zv arfarin. Dextrowarf'arini undergoes inetabolic tranisformiiation priim1arily by reduction of the ketonie fuinctioin of the acetonyl side chalinl to two or miiore secondary alcohols, which are excreted mncainly by the kidney into the uirinie (16) . Levowarfarin uindergoes inetal)olic tranisformiiation primarily by oxidation via rinig hy(lroxvlation of the coumlnarini nuicleuis to 7-hv,droxvlevowarf'arin, which is excreted by the liver mainilv into the bile andl evenituially into the stool (17) . It is proposed that the acetivity of the enzymnes controlling the ring oxidationi of' levowarfhiri minav l)e inhilitedl l)y phleniylbutazone. Sttudies witlh single enantionmorphs of warfarim sutpport this stuggestion (2) . This inhibition wouild imiipair the total body clearanice of levowarfarill and lead to hiigher blood levels andl a longer half-life Ph eqibtylbttazone and Warfarin in plasma for unchanged levowarfarin. It is also proposed that the activity of the enzymes controlling the side-chain reduction of dextrowarfarin perhaps is increased via enzymatic induction by phenylbutazone. This enzymatic stimulation would increase the total body clearance of dextrowarfarin and lead to lower blood levels and a shorter half-life in plasma for unchanged dextrowarfarin.
The greater quantity in the body of the more potent anticoagulant levowarfarin, even with a lesser quantity of total warfarin, would hinder the synthesis of the vitamin K-dependent clotting factors more completely and for a longer time in the presence of phenylbutazone (18) . This lessened synthesis of clotting factors would lead to a greater hypoprothrombinemic effect with both racemic and pseudoracemic warfarin. However, the alterations in the total body clearances of the enantiomorphs of warfarin by phenylbutazone, particularly that of levowarfarin, are modest compared with the marked augmentation ofthe hypoprothrombinemia in every subject tested. These data suggest that other factors contribute to the interaction.
A phenylbutazone-induced increase in the free fraction of racemic warfarin was reported by Aggeler and co-workers (1) and confirmed by Lewis et al. (2) . The importance of this alteration of albumin-bound warfarin by phenylbutazone was observed by Tillement et al. (19) . They found that phenylbutazone increased the free fraction of the three coumarin anticoagulants tested (acenocoumarol, ethyl biscoumacetate, and warfarin) but had no effect on that of the indanedione anticoagulants tested (fluorophenindione and phenindione). They correlated these binding data with the marked hypoprothrombinemic augmentation of coumarin anticoagulants and the absence of this interaction with indanediones (19) . Our data showed a highly significant increase in the Vd of levowarfarin, which is consistent with an increase in the free fraction of levowarfarin. The half-life of oral pseudoracemic warfarin administration by the one-compartment analysis reported herein, 36 h, is similar to administration of truly racemic warfarin intravenously by a two-compartment open model, 35 h (20) . It is also possible that the interaction results from a direct effect of phenylbutazone on the synthesis or the degradation of the vitamin K-dependent clotting factors. This possibility seems unlikely because phenylbutazone has no hypoprothrombinemic action by itself and has no effect on the degradation rate of clotting factors as evidenced by comparable prolongation of the prothrombin time for the first 48 h after the warfarin dose with and without phenylbutazone (21) . Thus, the most likely explanation for the interaction is a complex combination of effects: protein displacement and stereoselective metabolic changes.
The study reported herein demonstrated a stereoselective interaction of phenylbutazone on pseudoracemic warfarin. Other studies using separated enantiomorphs of racemic warfarin also demonstrated a stereoselective interaction with phenylbutazone: decreased clearance of levowarfarin and increased clearance of dextrowarfarin (3) . Phenylbutazone augmented the hypoprothrombinemia of levowarfarin but had little or no effect on that of dextrowarfarin. These findings suggest that the interaction of racemic warfarin and phenylbutazone may be lessened if racemic warfarin were replaced by dextrowarfarin for long-term therapy. Thus, long-term therapy with oral anticoagulants could become more stable and less dangerous. Substantiation of this possibility requires further detailed investigations to clarify the toxicity of dextrowarfarin at higher dosage and any significant interaction with phenylbutazone at those doses.
